Enanta Stock Plunges 9% As CEO Jay Luly Plans To Retire After 23 Years

The drug developer created a chief operating officer post and is searching for a successor to its longtime chief executive.

Share
Enanta Stock Plunges 9% As CEO Jay Luly Plans To Retire After 23 Years

Enanta Pharmaceuticals, which develops small molecule antiviral and immunology drugs, fell 8.62% to $11.13 in Wednesday trading, as of 10:56 a.m. ET, erasing about $31 million in market value. The drop came on the day the company said in an 8-K that CEO Jay R. Luly, 70, will retire by February 1, 2027, after 23 years leading it.

A new operating chief, a search for a successor

Enanta created a chief operating officer role and filled it with Tara L. Kieffer, a 16-year veteran of Vertex Pharmaceuticals who joined Enanta in 2020. Directors are considering both insiders and outsiders to succeed Luly, who will remain as an adviser.

The stock was on pace for its biggest one-day drop since March 5, when it fell 10.8%.

A royalty business and two RSV candidates

Enanta discovered glecaprevir, the hepatitis C antiviral AbbVie sells in MAVYRET in the US and MAVIRET elsewhere, and it earns royalties on those sales. Its own pipeline centers on respiratory syncytial virus (RSV), with two clinical-stage candidates, plus early-stage oral drugs for type 2 inflammatory diseases such as atopic dermatitis.

In its last quarterly results, revenue was $14.4 million, down from $18.3 million a year earlier, because AbbVie's reported hepatitis C sales fell. Cash and marketable securities totaled $211.5 million at June 30, and the company said that, with retained royalties, its cash should fund operations into fiscal 2029.

In that August release, Luly called it a "catalyst rich year ahead." The company expects to start a registrational trial of its RSV drug zelicapavir in the fourth quarter of 2026 and to report topline data from a Phase 1 trial of EDP-978, an oral urticaria drug, that quarter.

Down 23% this year

Enanta shares were down about 23% year to date at Tuesday's close, while the S&P 500 was up about 13% over the same span. That left the stock 28% below its highest close of the past year, set on December 26, 2025.

Enanta is scheduled to report its next quarterly results on Monday, November 16.

Sources

More on Enanta Pharmaceuticals

All Enanta Pharmaceuticals (ENTA) coverage →